ASP Isotopes (ASPI) to Release Quarterly Earnings on Monday

Key Points

• ASP Isotopes is set to release its Q2 2025 earnings on August 18th, expected to show a loss of $0.11 per share and revenue of $1.60 million.
• The stock price of ASP Isotopes recently opened at $9.32, with analysts noting a price target increase from $8.50 to $11.00 by Canaccord Genuity.
• An institutional investor raised its stake in ASP Isotopes by 9.4%, bringing total institutional ownership to 16.80% of the company’s shares.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Monday, August 18th. Analysts expect ASP Isotopes to post earnings of ($0.11) per share and revenue of $1.60 million for the quarter.

ASP Isotopes Trading Down 3.7%

ASPI opened at $9.32 on Monday. The firm has a market cap of $781.95 million, a price-to-earnings ratio of -15.28 and a beta of 3.36. ASP Isotopes has a 52 week low of $1.95 and a 52 week high of $10.82. The business's 50 day moving average is $8.43 and its two-hundred day moving average is $6.50. The company has a quick ratio of 7.17, a current ratio of 7.21 and a debt-to-equity ratio of 0.80.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group lifted their price target on ASP Isotopes from $8.50 to $11.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st.

Institutional Inflows and Outflows

An institutional investor recently raised its position in ASP Isotopes stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) by 9.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,613 shares of the company's stock after purchasing an additional 2,709 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in ASP Isotopes were worth $148,000 at the end of the most recent reporting period. 16.80% of the stock is currently owned by institutional investors and hedge funds.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.